HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Defective glucose counterregulation limits intensive therapy of diabetes mellitus.

AbstractDefective recovery from insulin-induced hypoglycemia, due to combined deficiencies of glucagon and epinephrine secretory responses to plasma glucose decrements, occurs in some patients with insulin-dependent diabetes mellitus (IDDM). Patients with IDDM determined to have inadequate glucose counterregulation during an insulin infusion test (40 mU X kg-1 X h-1) with bedside plasma glucose monitoring and clinical observation have been found to have a 25-fold greater risk of severe hypoglycemia during subsequent intensive therapy than patients with adequate glucose counterregulation. Thus, the efficacy of the glucose counterregulatory systems determines the limits of intensive therapy of IDDM.
AuthorsJ V Santiago, N H White, D A Skor, L A Levandoski, D M Bier, P E Cryer
JournalThe American journal of physiology (Am J Physiol) Vol. 247 Issue 2 Pt 1 Pg. E215-20 (Aug 1984) ISSN: 0002-9513 [Print] UNITED STATES
PMID6380308 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Blood Glucose
  • Insulin
Topics
  • Blood Glucose (metabolism)
  • Diabetes Mellitus, Type 1 (blood, drug therapy)
  • Humans
  • Infusions, Parenteral
  • Insulin (administration & dosage, diagnostic use, therapeutic use)
  • Kinetics
  • Reference Values

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD